Siemens Healthcare Diagnostics Products Gmbh

Dade Behring Marburg Gmbh

Thomas Wissel

Harald Althaus

Herbert Schwarz

Bodo Fischer

Norbert F Zander

Michael Kraus

Andreas Rechner

Andreas Kappel

Sabine Pilgrim

Hubert Nettelhoff

Heinz-Georg Kandel

Hermann Keuper

Sina Stephan

Reiner Muth

The present invention pertains to the field of coagulation diagnostics and relates to a prothrombin time reagent on the basis of recombinant or native tissue factor protein and phospholipids, which reagent can be stabilized by the addition of an iron chelator from the groups of siderophores and 3,5-diphenyl-1,2,4-triazoles.

Iron chelator-containing prothrombin time reagent

A homogeneous method of determining inhibitors of proteolytically active coagulation factors (anticoagulants) in a sample, in particular direct thrombin and factor Xa inhibitors, and also a test kit to be used in such a method. Use is made of ligands which bind to the proteolytically active coagulation factor but are not cleaved by the latter and compete with the anticoagulant to be determined.

Method of determining inhibitors of coagulation

The invention relates to peptides with the Marburg I polymorphism of FSAP and to their preparation and uses, in particular in therapy and diagnosis. The peptides are suitable for use as immunizing antigens for preparing FSAP MR I specific antibodies.

Peptides with the marburg I polymorphism of factor VII-activating protease (FSAP) and their preparation and uses

The invention relates to analytical methods in which the partition of a labeled substance between a liquid and a solid phase is determined. The assays include solid-phase reagents which can be particulate or monolithic such as, for example, a coated tube. Assays of this type are known per se to the person skilled in the art and include immunoassays and immunometric assays.

Methods for determination of an analyte

The invention relates to antibodies which are directed against the FSAP Marburg I variant and to their preparation and use, in particular in therapy and diagnosis. The antibodies are characterized by the fact that they bind specifically to the FSAP MR I variant but not to the FSAP wild-type protein or other mutant variants which are characterized by amino acid substitutions at other positions in the FSAP protein.

Antibodies which are directed against the Marburg I polymorphism of factor VII-activating protease (FSAP), and their preparation and use

The present invention relates to a process for increasing the FVII sensitivity of a thromboplastin reagent by means of heat treatment.

Growing community of inventors

Lahntal, Germany

Thomas Wissel